Minimally Invasive Transplantation of IPSC-derived ALDHhiSSCloVLA4+ Neural Stem Cells Effectively Improves the Phenotype of an Amyotrophic Lateral Sclerosis Model

Overview

Journal Hum Mol Genet

Specialties Genetics
Molecular Biology

Date 2013 Sep 6

PMID 24006477

Citations 52

Authors

Monica Nizzardo

Chiara Simone

Federica Rizzo

Margherita Ruggieri

Sabrina Salani

Giulietta Riboldi

Irene Faravelli

Chiara Zanetta

Nereo Bresolin

Giacomo P Comi

Stefania Corti

Affiliations

Soon will be listed here.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease characterized by the degeneration of motor neurons. Currently, there is no effective therapy for ALS. Stem cell transplantation is a potential therapeutic strategy for ALS, and the reprogramming of adult somatic cells into induced pluripotent stem cells (iPSCs) represents a novel cell source. In this study, we isolated a specific neural stem cell (NSC) population from human iPSCs based on high aldehyde dehydrogenase activity, low side scatter and integrin VLA4 positivity. We assessed the therapeutic effects of these NSCs on the phenotype of ALS mice after intrathecal or intravenous injections. Transplanted NSCs migrated and engrafted into the central nervous system via both routes of injection. Compared with control ALS, treated ALS mice exhibited improved neuromuscular function and motor unit pathology and significantly increased life span, in particular with the systemic administration of NSCs (15%). These positive effects are linked to multiple mechanisms, including production of neurotrophic factors and reduction of micro- and macrogliosis. NSCs induced a decrease in astrocyte number through the activation of the vanilloid receptor TRPV1. We conclude that minimally invasive injections of iPSC-derived NSCs can exert a therapeutic effect in ALS. This study contributes to advancements in iPSC-mediated approaches for treating ALS and other neurodegenerative diseases.

Citing Articles

Calvo B, Schembri-Wismayer P, Duran-Alonso M Cells. 2025; 14(5).

PMID: 40072076 PMC: 11898746. DOI: 10.3390/cells14050347.

Stem Cell Therapy for the Treatment of Amyotrophic Lateral Sclerosis: Comparison of the Efficacy of Mesenchymal Stem Cells, Neural Stem Cells, and Induced Pluripotent Stem Cells.

Frawley L, Taylor N, Sivills O, McPhillamy E, To T, Wu Y Biomedicines. 2025; 13(1).

PMID: 39857620 PMC: 11763168. DOI: 10.3390/biomedicines13010035.

Neural Stem/Progenitor Cell Therapy in Patients and Animals with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis.

Zhang J, Guo R, Zhou Z, Fu Z, Akogo H, Li Y Mol Neurobiol. 2025; .

PMID: 39821843 DOI: 10.1007/s12035-024-04682-8.

Human iPSC-derived neural stem cells displaying radial glia signature exhibit long-term safety in mice.

Luciani M, Garsia C, Beretta S, Cifola I, Peano C, Merelli I Nat Commun. 2024; 15(1):9433.

PMID: 39487141 PMC: 11530573. DOI: 10.1038/s41467-024-53613-7.

Emerging strategies for nerve repair and regeneration in ischemic stroke: neural stem cell therapy.

Wang S, He Q, Qu Y, Yin W, Zhao R, Wang X Neural Regen Res. 2024; 19(11):2430-2443.

PMID: 38526280 PMC: 11090435. DOI: 10.4103/1673-5374.391313.

References

Marchetto M, Muotri A, Mu Y, Smith A, Cezar G, Gage F . Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008; 3(6):649-57. DOI: 10.1016/j.stem.2008.10.001. View

Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, OBanion M . ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci. 2008; 11(4):420-2. PMC: 2895310. DOI: 10.1038/nn2073. View

Corti S, Locatelli F, Papadimitriou D, Donadoni C, Del Bo R, Crimi M . Transplanted ALDHhiSSClo neural stem cells generate motor neurons and delay disease progression of nmd mice, an animal model of SMARD1. Hum Mol Genet. 2005; 15(2):167-87. DOI: 10.1093/hmg/ddi446. View

Reagan-Shaw S, Nihal M, Ahmad N . Dose translation from animal to human studies revisited. FASEB J. 2007; 22(3):659-61. DOI: 10.1096/fj.07-9574LSF. View

Yamanaka K, Boillee S, Roberts E, Garcia M, McAlonis-Downes M, Mikse O . Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci U S A. 2008; 105(21):7594-9. PMC: 2396671. DOI: 10.1073/pnas.0802556105. View

Ferraiuolo L, Kirby J, Grierson A, Sendtner M, Shaw P . Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011; 7(11):616-30. DOI: 10.1038/nrneurol.2011.152. View

Ludolph A, Brettschneider J, Weishaupt J . Amyotrophic lateral sclerosis. Curr Opin Neurol. 2012; 25(5):530-5. DOI: 10.1097/WCO.0b013e328356d328. View

Teng Y, Benn S, Kalkanis S, Shefner J, Onario R, Cheng B . Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci Transl Med. 2012; 4(165):165ra164. DOI: 10.1126/scitranslmed.3004579. View

Pluchino S, Zanotti L, Rossi B, Brambilla E, Ottoboni L, Salani G . Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature. 2005; 436(7048):266-71. DOI: 10.1038/nature03889. View

10.

Stock K, Kumar J, Synowitz M, Petrosino S, Imperatore R, Smith E . Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nat Med. 2012; 18(8):1232-8. PMC: 3480991. DOI: 10.1038/nm.2827. View

11.

Corti S, Nizzardo M, Nardini M, Donadoni C, Salani S, Simone C . Systemic transplantation of c-kit+ cells exerts a therapeutic effect in a model of amyotrophic lateral sclerosis. Hum Mol Genet. 2010; 19(19):3782-96. DOI: 10.1093/hmg/ddq293. View

12.

Gowing G, Svendsen C . Stem cell transplantation for motor neuron disease: current approaches and future perspectives. Neurotherapeutics. 2011; 8(4):591-606. PMC: 3210365. DOI: 10.1007/s13311-011-0068-7. View

13.

Boulis N, Federici T, Glass J, Lunn J, Sakowski S, Feldman E . Translational stem cell therapy for amyotrophic lateral sclerosis. Nat Rev Neurol. 2011; 8(3):172-6. DOI: 10.1038/nrneurol.2011.191. View

14.

DAmico E, Factor-Litvak P, Santella R, Mitsumoto H . Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013; 65:509-527. PMC: 3859834. DOI: 10.1016/j.freeradbiomed.2013.06.029. View

15.

Riboldi G, Nizzardo M, Simone C, Falcone M, Bresolin N, Comi G . ALS genetic modifiers that increase survival of SOD1 mice and are suitable for therapeutic development. Prog Neurobiol. 2011; 95(2):133-48. DOI: 10.1016/j.pneurobio.2011.07.009. View

16.

Corti S, Locatelli F, Papadimitriou D, Del Bo R, Nizzardo M, Nardini M . Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model. Brain. 2007; 130(Pt 5):1289-305. DOI: 10.1093/brain/awm043. View

17.

Corti S, Nizzardo M, Simone C, Falcone M, Nardini M, Ronchi D . Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med. 2012; 4(165):165ra162. PMC: 4722730. DOI: 10.1126/scitranslmed.3004108. View

18.

Nagai M, Aoki M, Miyoshi I, Kato M, Pasinelli P, Kasai N . Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci. 2001; 21(23):9246-54. PMC: 6763929. View

19.

Steinman L . A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol. 2009; 9(6):440-7. DOI: 10.1038/nri2548. View

20.

Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S . Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2013; 494(7435):100-4. DOI: 10.1038/nature11807. View